citalopram has been researched along with Sleep Initiation and Maintenance Disorders in 41 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Sleep Initiation and Maintenance Disorders: Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objectives were to characterize latent depression subtypes by symptoms, evaluate sex differences in and examine correlates of these subtypes, and examine the association between subtype and symptom remission after citalopram treatment." | 9.20 | The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2015) |
| "Among healthy perimenopausal and postmenopausal women with hot flashes, escitalopram at 10 to 20 mg/day compared with placebo reduced insomnia symptoms and improved subjective sleep quality at 8 weeks of follow-up." | 9.16 | Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. ( Ensrud, KE; Freeman, EW; Guthrie, KA; Joffe, H; Lacroix, AZ; Landis, CA; Larson, JC; Newton, KM; Reed, SD; Sternfeld, B; Woods, NF, 2012) |
| "To determine the efficacy and safety of citalopram hydrobromide therapy for repetitive behavior in children with autism spectrum disorders." | 9.14 | Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. ( Anagnostou, E; Bregman, JD; Donnelly, CL; Dukes, K; Hirtz, D; Hollander, E; King, BH; McCracken, JT; Ritz, L; Scahill, L; Sikich, L; Sullivan, L; Wagner, A, 2009) |
| "To construct a cost-utility model comparing escitalopram with sertraline in the treatment of major depressive disorders." | 7.74 | Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. ( Armstrong, EP; Haim Erder, M; Skrepnek, GH, 2007) |
| " Both treatments improved BI score, with no statistical difference, and were well tolerated, with few significant differences in treatment-associated adverse events." | 7.01 | The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression. ( Chen, S; Feng, L; He, J; Luan, X; Wang, Q; Xiao, M, 2021) |
| "Citalopram and venlafaxine are equally more effective than placebo in reducing sleep disturbance and severity of hot flashes, while citalopram is more effective in reducing frequency of hot flashes than venlafaxine." | 5.22 | Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial. ( Asadi, M; Davari-Tanha, F; Hadizadeh, H; Shariat, M; Shirazi, M; Soleymani-Farsani, M, 2016) |
| "The objectives were to characterize latent depression subtypes by symptoms, evaluate sex differences in and examine correlates of these subtypes, and examine the association between subtype and symptom remission after citalopram treatment." | 5.20 | The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2015) |
| "Among healthy perimenopausal and postmenopausal women with hot flashes, escitalopram at 10 to 20 mg/day compared with placebo reduced insomnia symptoms and improved subjective sleep quality at 8 weeks of follow-up." | 5.16 | Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. ( Ensrud, KE; Freeman, EW; Guthrie, KA; Joffe, H; Lacroix, AZ; Landis, CA; Larson, JC; Newton, KM; Reed, SD; Sternfeld, B; Woods, NF, 2012) |
| "To determine the efficacy and safety of citalopram hydrobromide therapy for repetitive behavior in children with autism spectrum disorders." | 5.14 | Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. ( Anagnostou, E; Bregman, JD; Donnelly, CL; Dukes, K; Hirtz, D; Hollander, E; King, BH; McCracken, JT; Ritz, L; Scahill, L; Sikich, L; Sullivan, L; Wagner, A, 2009) |
| " The rate of recurrence of the fluoxetine-associated adverse events was low, with headache (3 [27%] of 11 cases), nausea (2 [22%] of 9 cases), and decreased libido (5 [18%] of 28 cases) being the most common." | 5.10 | Citalopram treatment of fluoxetine-intolerant depressed patients. ( Calabrese, JR; Londborg, PD; Shelton, MD; Thase, ME, 2003) |
| "To characterize the association between functional impairment and major depression subtypes at baseline and to characterize changes in subtypes by functional impairment level in women receiving citalopram in level 1 of the Sequenced Treatment Alternatives to Relieve Depression trial." | 3.83 | Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2016) |
| " A 52-year-old man with a history of depression treated with escitalopram 10 mg/day, extended-release morphine 30 mg/day and zopiclone 15 mg/day was found unconscious at his home." | 3.74 | Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. ( Baranchuk, A; Gibson, K; Methot, M; Simpson, CS; Strum, D, 2008) |
| "To construct a cost-utility model comparing escitalopram with sertraline in the treatment of major depressive disorders." | 3.74 | Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. ( Armstrong, EP; Haim Erder, M; Skrepnek, GH, 2007) |
| "A 47-year-old white man with a history of bipolar disorder was being maintained on citalopram 40 mg once daily and zolpidem 5 mg at bedtime." | 3.72 | Somnambulism due to probable interaction of valproic acid and zolpidem. ( Bhatia, SC; Petty, F; Ramaswamy, S; Sattar, SP, 2003) |
| " Both treatments improved BI score, with no statistical difference, and were well tolerated, with few significant differences in treatment-associated adverse events." | 3.01 | The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression. ( Chen, S; Feng, L; He, J; Luan, X; Wang, Q; Xiao, M, 2021) |
| "Omega-3 supplements did not improve insomnia symptoms." | 2.87 | Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials. ( Anderson, GL; Carpenter, JS; Ensrud, KE; Freeman, EW; Guthrie, KA; Joffe, H; LaCroix, AZ; Larson, JC; Manson, JE; McCurry, SM; Morin, CM; Newton, KM; Otte, J; Reed, SD, 2018) |
| "Patients with comorbid depression and insomnia who experienced the first onset of both disorders in childhood are less responsive to the treatments offered herein than are those with adult onsets of these comorbid disorders." | 2.84 | Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study. ( Buysse, DJ; Edinger, JD; Fairholme, CP; Gehrman, P; Krystal, AD; Luther, J; Manber, R; Thase, ME; Wisniewski, S, 2017) |
| "Pre-treatment insomnia has been associated with poorer treatment outcomes in some antidepressant trials, leading to suggestions that combined treatment regimens may be more successful in this subgroup." | 2.80 | Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015) |
| "Many patients with major depressive disorder (MDD) who experience full symptomatic remission after antidepressant treatment still have residual depressive symptoms." | 2.75 | Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. ( Fava, M; Husain, MM; Miyahara, S; Nierenberg, AA; Rush, AJ; Trivedi, MH; Warden, D; Wisniewski, SR, 2010) |
| "Escitalopram was used as a control for assay sensitivity." | 2.75 | A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. ( Dellva, MA; Dubé, S; Jones, M; Kielbasa, W; Padich, R; Rao, P; Saha, A, 2010) |
| "Chronic insomnia and depression are often associated." | 2.74 | Validation of the sleep impact scale in patients with major depressive disorder and insomnia. ( Crawford, B; Joish, VN; Lasch, K; Qiu, C; Rosa, K; Zhu, Y, 2009) |
| "Insomnia impacts the course of major depressive disorder (MDD), hinders response to treatment, and increases risk for depressive relapse." | 2.73 | Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. ( Edinger, JD; Gress, JL; Kalista, T; Kuo, TF; Manber, R; San Pedro-Salcedo, MG, 2008) |
| "To determine the efficacy of eszopiclone combined with escitalopram oxalate in treating insomnia comorbid with GAD." | 2.73 | Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. ( Huang, H; Kinrys, G; Krishnan, R; Krystal, A; McCall, WV; Pollack, M; Roach, J; Roth, T; Rubens, R; Schaefer, K, 2008) |
| "Escitalopram was well tolerated." | 2.72 | An open-label study of escitalopram in body dysmorphic disorder. ( Phillips, KA, 2006) |
| "In continuation of a previous psychometric analysis of dose-response data for citalopram in depression, the corresponding study data for escitalopram is of interest, since escitalopram is the active enantiomer of citalopram and because citalopram was used as the active control." | 2.71 | Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. ( Andersen, HF; Bech, P; Cialdella, P; Pedersen, AG; Tanghøj, P, 2004) |
| "Citalopram was significantly more effective than placebo in the treatment of moderate-to-severe major depression, especially symptoms of depressed mood and melancholia, with particularly robust effects shown at doses of 40 and 60 mg/day." | 2.69 | Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. ( Feighner, JP; Overø, K, 1999) |
| "They suffer from insomnia, nocturnal panic attacks, fear of going to bed or falling asleep and drug- or alcohol-related symptoms such as withdrawal phenomena." | 2.39 | Sleep in panic disorders. ( Koponen, H; Leinonen, E; Lepola, U, 1994) |
| "Greater fatigue/insomnia was also associated with slower processing speed, while rumination/worry was associated with poorer episodic memory." | 1.91 | Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression. ( Conway, C; Elson, D; Kang, H; Sudol, K; Szymkowicz, SM; Taylor, WD, 2023) |
| "A total of 15 PTSD patients (36." | 1.35 | [Sleep spindles in post traumatic stress disorder: significant importance of selective serotonin reuptake inhibitors]. ( Dotan, Y; Pillar, G; Suraiya, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 19 (46.34) | 29.6817 |
| 2010's | 17 (41.46) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Sudol, K | 1 |
| Conway, C | 1 |
| Szymkowicz, SM | 1 |
| Elson, D | 1 |
| Kang, H | 1 |
| Taylor, WD | 1 |
| Szuhany, KL | 1 |
| Young, A | 1 |
| Mauro, C | 1 |
| Garcia de la Garza, A | 1 |
| Spandorfer, J | 1 |
| Lubin, R | 1 |
| Skritskaya, NA | 1 |
| Hoeppner, SS | 1 |
| Li, M | 1 |
| Pace-Schott, E | 1 |
| Zisook, S | 1 |
| Reynolds, CF | 1 |
| Shear, MK | 1 |
| Simon, NM | 1 |
| Xiao, M | 1 |
| Feng, L | 1 |
| Wang, Q | 1 |
| Luan, X | 1 |
| Chen, S | 1 |
| He, J | 1 |
| Guthrie, KA | 2 |
| Larson, JC | 2 |
| Ensrud, KE | 2 |
| Anderson, GL | 1 |
| Carpenter, JS | 1 |
| Freeman, EW | 2 |
| Joffe, H | 2 |
| LaCroix, AZ | 2 |
| Manson, JE | 1 |
| Morin, CM | 1 |
| Newton, KM | 2 |
| Otte, J | 1 |
| Reed, SD | 2 |
| McCurry, SM | 1 |
| Vijay, A | 1 |
| Becker, JE | 1 |
| Ross, JS | 1 |
| Fabbri, C | 1 |
| Marsano, A | 1 |
| Balestri, M | 1 |
| De Ronchi, D | 1 |
| Serretti, A | 1 |
| Kanaeva, LS | 1 |
| Dashkina, GK | 1 |
| Sung, SC | 1 |
| Wisniewski, SR | 2 |
| Luther, JF | 1 |
| Trivedi, MH | 2 |
| Rush, AJ | 2 |
| Ulbricht, CM | 2 |
| Rothschild, AJ | 2 |
| Lapane, KL | 2 |
| Davari-Tanha, F | 1 |
| Soleymani-Farsani, M | 1 |
| Asadi, M | 1 |
| Shariat, M | 1 |
| Shirazi, M | 1 |
| Hadizadeh, H | 1 |
| Edinger, JD | 3 |
| Manber, R | 2 |
| Buysse, DJ | 1 |
| Krystal, AD | 2 |
| Thase, ME | 2 |
| Gehrman, P | 1 |
| Fairholme, CP | 1 |
| Luther, J | 1 |
| Wisniewski, S | 1 |
| Abba-Aji, A | 1 |
| Bardoloi, P | 1 |
| Carney, CE | 1 |
| Kuchibhatla, M | 1 |
| Lachowski, AM | 1 |
| Bogouslavsky, O | 1 |
| Shapiro, CM | 1 |
| Baranchuk, A | 1 |
| Simpson, CS | 1 |
| Methot, M | 1 |
| Gibson, K | 1 |
| Strum, D | 1 |
| Dotan, Y | 1 |
| Suraiya, S | 1 |
| Pillar, G | 1 |
| Fava, M | 3 |
| Asnis, GM | 2 |
| Shrivastava, R | 1 |
| Lydiard, B | 2 |
| Bastani, B | 2 |
| Sheehan, D | 1 |
| Roth, T | 3 |
| Nierenberg, AA | 1 |
| Husain, MM | 1 |
| Warden, D | 1 |
| Miyahara, S | 1 |
| King, BH | 1 |
| Hollander, E | 1 |
| Sikich, L | 1 |
| McCracken, JT | 1 |
| Scahill, L | 1 |
| Bregman, JD | 1 |
| Donnelly, CL | 1 |
| Anagnostou, E | 1 |
| Dukes, K | 1 |
| Sullivan, L | 1 |
| Hirtz, D | 1 |
| Wagner, A | 1 |
| Ritz, L | 1 |
| Lasch, K | 1 |
| Joish, VN | 1 |
| Zhu, Y | 1 |
| Rosa, K | 1 |
| Qiu, C | 1 |
| Crawford, B | 1 |
| Dubé, S | 1 |
| Dellva, MA | 1 |
| Jones, M | 1 |
| Kielbasa, W | 1 |
| Padich, R | 1 |
| Saha, A | 1 |
| Rao, P | 1 |
| Todder, D | 1 |
| Caliskan, S | 1 |
| Baune, BT | 1 |
| Keers, R | 1 |
| Bonvicini, C | 1 |
| Scassellati, C | 1 |
| Uher, R | 1 |
| Placentino, A | 1 |
| Giovannini, C | 1 |
| Rietschel, M | 1 |
| Henigsberg, N | 1 |
| Kozel, D | 1 |
| Mors, O | 1 |
| Maier, W | 1 |
| Hauser, J | 1 |
| Souery, D | 1 |
| Mendlewicz, J | 1 |
| Schmäl, C | 1 |
| Zobel, A | 1 |
| Larsen, ER | 1 |
| Szczepankiewicz, A | 1 |
| Kovacic, Z | 1 |
| Elkin, A | 1 |
| Craig, I | 1 |
| McGuffin, P | 1 |
| Farmer, AE | 1 |
| Aitchison, KJ | 1 |
| Gennarelli, M | 1 |
| Shrivastava, RK | 1 |
| Sheehan, DV | 1 |
| Sternfeld, B | 1 |
| Landis, CA | 1 |
| Woods, NF | 1 |
| Pachman, DR | 1 |
| Morgenthaler, TI | 1 |
| Loprinzi, CL | 1 |
| Calabrese, JR | 1 |
| Londborg, PD | 1 |
| Shelton, MD | 1 |
| Sattar, SP | 1 |
| Ramaswamy, S | 1 |
| Bhatia, SC | 1 |
| Petty, F | 1 |
| Bech, P | 1 |
| Tanghøj, P | 1 |
| Cialdella, P | 1 |
| Andersen, HF | 1 |
| Pedersen, AG | 1 |
| Pallanti, S | 1 |
| Quercioli, L | 1 |
| Bruscoli, M | 1 |
| Wingen, M | 1 |
| Bothmer, J | 1 |
| Langer, S | 1 |
| Ramaekers, JG | 1 |
| Phillips, KA | 1 |
| Csoka, AB | 1 |
| Shipko, S | 1 |
| Fujiki, N | 1 |
| Armstrong, EP | 1 |
| Skrepnek, GH | 1 |
| Haim Erder, M | 1 |
| Gress, JL | 1 |
| San Pedro-Salcedo, MG | 1 |
| Kuo, TF | 1 |
| Kalista, T | 1 |
| Pollack, M | 1 |
| Kinrys, G | 1 |
| Krystal, A | 1 |
| McCall, WV | 1 |
| Schaefer, K | 1 |
| Rubens, R | 1 |
| Roach, J | 1 |
| Huang, H | 1 |
| Krishnan, R | 1 |
| Lepola, U | 1 |
| Koponen, H | 1 |
| Leinonen, E | 1 |
| Feighner, JP | 1 |
| Overø, K | 1 |
| Robinson, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Menopausal Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) 04: A Pilot Trial of Telephone-Based Cognitive-Behavioral Therapy for Midlife Women With Menopause-related Sleep Disturbance[NCT01936441] | 106 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Menopause Strategies: Finding Lasting Answers for Symptoms and Health: Efficacy of a Selective Serotonin Reuptake Inhibitor (SSRI) for Menopausal Symptoms in Midlife Women[NCT00894543] | 205 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation[NCT01178892] | 355 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause[NCT05346445] | 91 participants (Actual) | Interventional | 2021-01-20 | Completed | |||
| MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and the SNRI Venlafaxine XR for Treatment of Menopausal Symptoms[NCT01418209] | 339 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Piloting an Adaption of Cognitive Behavioral Therapy for Insomnia for Shift Workers (CBTI-Shift)[NCT05965609] | 60 participants (Anticipated) | Interventional | 2023-12-08 | Recruiting | |||
| Efficacy Of Switching From SSRI to Desvenlafaxine on Cognitive Function In Patients With an Acute Episode of Major Depression[NCT03432221] | 36 participants (Anticipated) | Observational | 2018-04-03 | Recruiting | |||
| Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior[NCT00086645] | Phase 2 | 149 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Comparison of Zolpidem Tartrate Extended-Release vs. Placebo in Treatment of Insomnia Associated With Newly Diagnosed Major Depressive Disorder(MDD) or Untreated MDD Relapse, When Used Concomitantly With Escitalopram[NCT00296179] | Phase 4 | 372 participants | Interventional | 2006-02-28 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease[NCT03977441] | Phase 4 | 240 participants (Anticipated) | Interventional | 2019-07-31 | Not yet recruiting | ||
| Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women With VMS.[NCT02040532] | 32 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| Efficacy Potential of an Internet-based Sleep Program to Improve Sleep Quality in People With HIV[NCT02571595] | 27 participants (Actual) | Interventional | 2015-05-31 | Terminated | |||
| [NCT00149825] | Phase 2 | 30 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Feasibility of a Personalized Short Message Service Intervention for Insomnia[NCT05108194] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-11-15 | Recruiting | ||
| The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.[NCT00235508] | Phase 4 | 420 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in daily hot flash frequency was calculated as the daily mean difference between baseline and week 4. Baseline was calculated as the daily mean of the daily frequencies for the first two screening weeks. Week 4 was calculated as the daily mean of the daily frequencies during the week prior to the week 4 visit. (NCT00894543)
Timeframe: week 4 minus baseline
| Intervention | Hot flashes/day (Mean) |
|---|---|
| Escitalopram | -4.37 |
| Placebo | -2.49 |
Change in daily hot flash frequency was calculated as the daily mean difference between baseline and week 8. Baseline was calculated as the daily mean of the frequencies for the first two screening weeks. Week 8 was calculated as the daily mean of the daily frequencies during the week prior to the week 8 visit. (NCT00894543)
Timeframe: week 8 minus baseline
| Intervention | Hot flashes/day (Mean) |
|---|---|
| Escitalopram | -4.60 |
| Placebo | -3.20 |
"Change in daily hot flash bother was calculated as the mean difference between baseline and week 4. Baseline was calculated as the daily mean of the highest daily bother ratings during the first two screening weeks. Week 4 was calculated as the daily mean of the highest of the daily bother ratings during the week prior to the week 4 visit.~Hot flash bother was rated as 1 (none), 2 (a little), 3 (moderately), or 4 (a lot) as adopted from the Study of Women Across the Nation (SWAN)." (NCT00894543)
Timeframe: week 4 minus baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | -0.59 |
| Placebo | -0.29 |
"Change in daily hot flash severity from baseline to week 4 was calculated as the mean difference in hot flash severity ratings between baseline and week 4. Baseline was calculated as the daily mean from the first two weeks of hot flash severity ratings. Week 4 severity ratings were calculated as the daily mean from the ratings for the week prior to the week 4 visit.~Hot flash severity was rated as 1 (mild), 2 (moderate), or 3 (severe) as adopted from the Study of Women Across the Nation (SWAN)." (NCT00894543)
Timeframe: week 4 minus baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | -0.43 |
| Placebo | -0.23 |
Change in daily hot flash severity between baseline & week 8 was calculated as mean difference. Baseline severity ratings were calculated as daily mean ratings for the first two screening weeks pre-baseline. Week 8 severity ratings were calculated as daily mean ratings during the week before week 8. Modified intention to treat analysis included all randomized participants who provided diary data, which were analyzed regardless of adherence to treatment assignment. Hot flash severity was rated as 1 (mild), 2 (moderate), or 3 (severe) as adopted from the Study of Women Across the Nation (SWAN). (NCT00894543)
Timeframe: week 8 minus baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | -0.53 |
| Placebo | -0.30 |
Baseline hot flash frequency per day was calculated as the daily mean of the daily totals reported during the first two screening weeks. (NCT00894543)
Timeframe: Baseline
| Intervention | Hot flashes/day (Mean) |
|---|---|
| Escitalopram | 9.88 |
| Placebo | 9.66 |
"Daily Hot flash bother scores were calculated by selecting the highest bother rating for hot flashes or night sweats for each woman in each 24-hour day. The score was set to missing on on any day data were missing or or hot flashes equaled 0. The daily mean of daily ratings for the first 2 screening weeks is reported.~Hot flash bother was rated as 1 (none), 2 (a little), 3 (moderately), or 4 (a lot) as adopted from the Study of Women Across the Nation (SWAN)." (NCT00894543)
Timeframe: Baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | 3.12 |
| Placebo | 3.16 |
"Daily hot flash severity scores were calculated by by selecting the highest severity rating for hot flashes or night sweats for each woman in each 24-hour day. The score was set to missing on on any day data were missing or or hot flashes equaled 0. The daily mean of daily ratings for the first 2 screening weeks is reported.~Hot flash severity was rated as 1 (mild), 2 (moderate), or 3 (severe) as adopted from the Study of Women Across the Nation (SWAN)." (NCT00894543)
Timeframe: Baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | 2.16 |
| Placebo | 2.19 |
Change in daily hot flash bother between baseline & week 8 was calculated as mean difference. Baseline daily bother was the mean of the highest daily ratings for two screening weeks pre-baseline. Week 8 bother was daily mean of the highest daily bother ratings during the week before week 8. Modified intention to treat analysis included all randomized participants who provided diary data, which were analyzed regardless of adherence to treatment assignment. Hot flash bother was rated as 1 (none), 2 (a little), 3 (moderately), 4 (a lot) as adopted from the Study of Women Across the Nation (SWAN). (NCT00894543)
Timeframe: week 8 minus baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram | -0.63 |
| Placebo | -0.39 |
Measured by self-report diary twice daily (day and night) for 7 days. Bothersomeness ratings ranged from 0 to 3 with lower numbers being less bothersome and higher numbers being more bothersome. Data from the day and night bothersomeness ratings were averaged for a single daily score. The single daily scores for the week prior to the week 4 study assessment were summed and averaged to produce a mean daily VMS bothersomeness for week 4. (NCT01418209)
Timeframe: Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 1.6 |
| Venlafaxine XR | 1.6 |
| Placebo | 1.7 |
Measured by self-report diary twice daily (day and night) for 7 days. Bothersomeness ratings ranged from 0 to 3 with lower numbers being less bothersome and higher numbers being more bothersome. Data from the day and night bothersomeness ratings were averaged for a single daily score. The single daily scores for the week prior to the week 8 study assessment were summed and averaged to produce a mean daily VMS bothersomeness for week 8. (NCT01418209)
Timeframe: Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 1.4 |
| Venlafaxine XR | 1.4 |
| Placebo | 1.6 |
Measured by self-report diary twice daily (day and night). The day and night frequencies were summed to produce a single number of hot flashes per day. The single number of hot flashes per day were summed and averaged for one week prior to the week 8 study assessment to produce a mean daily frequency for week 8. (NCT01418209)
Timeframe: Week 8
| Intervention | number of hot flashes per day (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 3.9 |
| Venlafaxine XR | 4.4 |
| Placebo | 5.5 |
Measured by self-report diary twice daily (day and night). The day and night frequencies were summed to produce a single number of hot flashes per day. The single number of hot flashes per day were summed and averaged for one week prior to the week 4 study assessment to produce a mean daily frequency for week 4. (NCT01418209)
Timeframe: Week 4
| Intervention | number of hot flashes per day (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 5.3 |
| Venlafaxine XR | 5.1 |
| Placebo | 5.8 |
The perceived hot flash related daily interference scale (HFRDIS) is a tool for assessing the impact of hot flashes on quality of life. There are 10 questions with each having a score ranging from 0 to 10. The scores from each question are summed for a total score ranging from 0 to 100. Lower numbers indicate less interference and higher numbers indicate more interference. (NCT01418209)
Timeframe: Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 18.3 |
| Venlafaxine XR | 19.8 |
| Placebo | 24.2 |
The perceived hot flash related daily interference scale (HFRDIS) is a tool for assessing the impact of hot flashes on quality of life. There are 10 questions with each having a score ranging from 0 to 10. The scores from each question are summed for a total score ranging from 0 to 100. Lower numbers indicate less interference and higher numbers indicate more interference. (NCT01418209)
Timeframe: Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 14.6 |
| Venlafaxine XR | 18.3 |
| Placebo | 21.5 |
Measured by self-report diary twice daily (day and night) for 7 days. Severity ratings ranged from 0 to 3 with lower numbers being less severe and higher numbers being more severe. Data from the day and night severity ratings were averaged for a single daily score. The single daily scores for the week prior to the week 4 study assessment were summed and averaged to produce a mean daily VMS severity for week 4. (NCT01418209)
Timeframe: Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 0.7 |
| Venlafaxine XR | 0.7 |
| Placebo | 0.8 |
Measured by self-report diary twice daily (day and night) for 7 days. Severity ratings ranged from 0 to 3 with lower numbers being less severe and higher numbers being more severe. Data from the day and night severity ratings were averaged for a single daily score. The single daily scores for the week prior to the week 8 study assessment were summed and averaged to produce a mean daily VMS severity for week 8. (NCT01418209)
Timeframe: Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Low-dose 17-ß-estradiol With Progesterone Taper | 0.6 |
| Venlafaxine XR | 0.6 |
| Placebo | 0.7 |
"The Quality of life-Menopause specific is assessed by the Menopause Specific Quality of Life (MENQOL).~The MENQOL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of one of four domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29). Items pertaining to a specific symptom are rated as present or not present, and if present, how bothersome on a zero (not bothersome) to six (extremely bothersome) scale. Means are computed for each subscale by dividing the sum of the domain's items by the number of items within that domain. Non-endorsement of an item is scored a 1 and endorsement a 2, plus the number of the particular rating, so that the possible score on any item ranges from 1-8. Total score also ranges from 1-8." (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| MENQOL scores at baseline | MENQOL scores at study completion | |
| Open-label Gabapentin | 3.2 | 1.9 |
Quality of life-Overall was assessed with the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). The Q-LES-Q is a 16-item self-report questionnaire that assesses enjoyment of and satisfaction with life. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70 with higher scores indicating higher quality of life enjoyment and satisfaction. (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Q-LES-Q scores at baseline | Q-LES-Q scores at study completion | |
| Open-label Gabapentin | 60.3 | 61.7 |
"Severity of insomnia was measured throughout the study using the Insomnia Severity Index (ISI) .The ISI is a 7-item scale that evaluates the severity of insomnia retrospectively over the past week. The scale is more specific to insomnia symptoms than the Pittsburgh scale (PSQI), which focuses more broadly on overall sleep quality.~The ISI score ranges from a minimum of 0 to 28. A score of 0-7=no clinically significant insomnia, 8-14=subthreshold insomnia, 5-21=clinical insomnia (moderate severity), 22-28=clinical insomnia (severe), with higher values indicating more severe insomnia." (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| mean ISI score at baseline | mean ISI score at study completion | |
| Open-label Gabapentin | 15.6 | 6.0 |
"Sleep quality and disturbances during the past month were assessed with the Pittsburgh Sleep Quality Index (PSQI). The PSQI also incorporates daytime functioning into the total score.~In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality." (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| PSQI total score at baseline | PSQI total score at study completion | |
| Open-label Gabapentin | 9.6 | 4.9 |
Vasomotor symptoms (VMS) were tracked and quantified prospectively using a daily hot flash diary. The hot flash diary was adapted from a 7-day self-report tool for vasomotor symptoms originally developed by the North Central Cancer Treatment Group (NCCTG). The diary asks for the subject to log number of hot flashes during the day and night, severity of hot flashes during day and night, and how bothersome the hot flashes were during day and night. Vasomotor symptoms were also systematically assessed at baseline, week 4, and week 7 using the Hot Flash-Related Daily Interference Scale (HFRDIS), a 10-item self-report questionnaire to determine perceived hot flash interference with quality of life and daily activities. (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | vasomotor symptoms (VMS) per day (Mean) | |
|---|---|---|
| mean VMS per day at baseline | mean VMS per day at study completion | |
| Open-label Gabapentin | 4.1 | 2.2 |
Vasomotor symptoms (VMS) were tracked and quantified prospectively using a daily hot flash diary. The hot flash diary was adapted from a 7-day self-report tool for vasomotor symptoms originally developed by the North Central Cancer Treatment Group (NCCTG). The diary asks for the subject to log number of hot flashes during the day and night, severity of hot flashes during day and night, and how bothersome the hot flashes were during day and night. Vasomotor symptoms were also systematically assessed at baseline, week 4, and week 7 using the Hot Flash-Related Daily Interference Scale (HFRDIS), a 10-item self-report questionnaire to determine perceived hot flash interference with quality of life and daily activities. (NCT02040532)
Timeframe: Baseline, study completion at 7 weeks
| Intervention | vasomotor symptoms (VMS) per night (Mean) | |
|---|---|---|
| mean VMS per night at baseline | mean VMS per night at study completion | |
| Open-label Gabapentin | 3.5 | 1.1 |
"Percent of participants in depressive remission at 12 weeks. Remission of depression was required both an HRSD score ≤ 7 and absence of the two core symptoms of MDD based on the depression module of the SCID.~The HRSD (Hamilton Rating of Depression Scale) measure depressive symptom severity. TIt has 17 items. The score ranges between 0 and 48. A score below 7 represents minimal symptoms.~The SCID rates 9 symptoms of depression as present or absent. The two core symptoms of depression are sadness and anhedonia (low motivation and/or enjoyment in significant life domains)." (NCT00149825)
Timeframe: After 12 weeks or at the last available time point
| Intervention | percent of participants (Number) |
|---|---|
| MED+CBTI | 61.5 |
| MED+CTRL | 33.3 |
Percent of participants in insomnia remission. Remission of insomnia was defined by an Insomnia Severity Index (ISI)score < 8. The ISI (Insomnia Severity index) scores range between 0 and 38. A score < 8 indicates absence of insomnia. (NCT00149825)
Timeframe: After 12 weeks or at the last available time point
| Intervention | percent (Number) |
|---|---|
| MED+CBTI | 50.0 |
| MED+CTRL | 7.7 |
1 review available for citalopram and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Sleep in panic disorders.
Topics: Adult; Child; Citalopram; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administra | 1994 |
25 trials available for citalopram and Sleep Initiation and Maintenance Disorders
15 other studies available for citalopram and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression.
Topics: Aged; Anhedonia; Citalopram; Cognition; Depression; Escitalopram; Fatigue; Humans; Sleep Initiation | 2023 |
Patterns and predictors of off-label prescription of psychiatric drugs.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Citalopram; Cross-Sectional Studies; Drug Presc | 2018 |
Clinical features and drug induced side effects in early versus late antidepressant responders.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Foll | 2013 |
Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depression; Fe | 2016 |
Paradoxical insomnia in a patient taking zopiclone.
Topics: Antidepressive Agents; Azabicyclo Compounds; Citalopram; Deprescriptions; Depressive Disorder, Major | 2017 |
Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines.
Topics: Antidepressive Agents, Second-Generation; Arrhythmias, Cardiac; Azabicyclo Compounds; Benzodiazepine | 2008 |
[Sleep spindles in post traumatic stress disorder: significant importance of selective serotonin reuptake inhibitors].
Topics: Citalopram; Electromyography; Electrooculography; Humans; Paroxetine; Reference Values; Selective Se | 2008 |
Longitudinal changes of day-time and night-time gross motor activity in clinical responders and non-responders of major depression.
Topics: Actigraphy; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Circadian Rh | 2009 |
Hot flashes and antidepressant agents: uneasy bedfellows.
Topics: Citalopram; Female; Hot Flashes; Humans; Menopause; Selective Serotonin Reuptake Inhibitors; Sleep; | 2012 |
Somnambulism due to probable interaction of valproic acid and zolpidem.
Topics: Bipolar Disorder; Citalopram; Depression; Drug Interactions; Drug Therapy, Combination; Humans; Male | 2003 |
[Motivational therapy can fail here. Sleep disorders in depressions].
Topics: Antidepressive Agents, Tricyclic; Arousal; Citalopram; Depressive Disorder, Major; Dose-Response Rel | 2004 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonist | 2006 |
Associated Professional Sleep Societies--SLEEP 2006 20th Anniversary Meeting. 17-22 June 2006, Salt Lake City, UT, USA.
Topics: Animals; Citalopram; Histamine Antagonists; Humans; Hypnotics and Sedatives; Indenes; Receptors, His | 2006 |
Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Decision Support Techniques; Depres | 2007 |
Are newer antidepressants really "better tolerated"?
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Contusions; Depressive Disorder; Female | 2001 |